Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?

chronic lymphoproliferative disorder of natural killer (NK) cells hepatocytes killer immunoglobulin-like receptors natural killer cells pneumocytes retroviral infection

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 02 10 2020
accepted: 30 11 2020
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 16 2 2021
Statut: epublish

Résumé

Large granular lymphocyte leukemias (LGLL) are sustained by proliferating cytotoxic T cells or NK cells, as happens in Chronic Lymphoproliferative Disorder of Natural Killer cells (CLPD-NK), whose etiology is only partly understood. Different hypotheses have been proposed on the original events triggering NK cell hyperactivation and transformation, including a role of viral agents. In this perspective, we revise the lines of evidence that suggested a pathogenetic role in LGLL of the exposure to retroviruses and that identified Epstein Barr Virus (EBV) in other NK cell leukemias and lymphomas and focus on the contrasting data about the importance of viral agents in CLPD-NK. EBV was detected in aggressive NK leukemias but not in the indolent CLPD-NK, where seroreactivity against HTLV-1 retrovirus envelope BA21 protein antigens has been reported in patients, although lacking clear evidence of HTLV infection. We next present original results of whole exome sequencing data analysis that failed to identify viral sequences in CLPD-NK. We recently demonstrated that proliferating NK cells of patients harbor several somatic lesions likely contributing to sustain NK cell proliferation. Thus, we explore whether "neoantigens" similar to the BA21 antigen could be generated by aberrancies present in the leukemic clone. In light of the literature and new data, we evaluated the intriguing hypothesis that NK cell activation can be caused by retroviral agents located outside the hematopoietic compartment and on the possible mechanisms involved with the prospects of immunotherapy-based approaches to limit the growth of NK cells in CLPD-NK disease.

Identifiants

pubmed: 33585237
doi: 10.3389/fonc.2020.613570
pmc: PMC7873950
doi:

Types de publication

Journal Article

Langues

eng

Pagination

613570

Informations de copyright

Copyright © 2021 Giussani, Binatti, Calabretto, Gasparini, Teramo, Vicenzetto, Barilà, Facco, Coppe, Semenzato, Bortoluzzi and Zambello.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Immunol. 2012 Nov 01;3:326
pubmed: 23125843
J Virol. 2005 Oct;79(19):12507-14
pubmed: 16160178
Front Pediatr. 2018 Oct 10;6:292
pubmed: 30364049
AIDS Res Hum Retroviruses. 2015 Feb;31(2):242-9
pubmed: 25295378
Leuk Res. 1994 Jun;18(6):423-9
pubmed: 8207960
Blood. 1993 May 15;81(10):2723-7
pubmed: 8387836
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1668-72
pubmed: 14757818
Bioinformatics. 2013 Jan 15;29(2):266-7
pubmed: 23162058
Leuk Res. 2005 Apr;29(4):381-7
pubmed: 15725471
Gastroenterology. 2018 Nov;155(5):1366-1371.e3
pubmed: 30031767
PLoS One. 2016 Sep 20;11(9):e0163297
pubmed: 27649529
J Clin Invest. 1989 Jul;84(1):51-5
pubmed: 2544630
Leuk Lymphoma. 1996 Oct;23(3-4):371-4
pubmed: 9031119
J Biomed Biotechnol. 2011;2011:298348
pubmed: 21629750
BMC Med Genomics. 2019 Jun 17;12(1):88
pubmed: 31208405
Br J Haematol. 2000 Mar;108(4):717-23
pubmed: 10792274
Blood. 2005 Dec 1;106(12):3926-31
pubmed: 16091452
Haematologica. 2010 Oct;95(10):1722-9
pubmed: 20410181
Retrovirology. 2008 Sep 22;5:86
pubmed: 18808681
Int J Immunogenet. 2020 Feb;47(1):1-12
pubmed: 31755661
Front Immunol. 2017 May 26;8:581
pubmed: 28603523
Nat Commun. 2018 Apr 19;9(1):1567
pubmed: 29674644
Genome Res. 2016 Dec;26(12):1721-1729
pubmed: 27852649
Blood. 2008 Dec 1;112(12):4694-8
pubmed: 18791165
Front Oncol. 2019 May 14;9:386
pubmed: 31139570
Chest. 2020 Dec;158(6):2602-2609
pubmed: 32919988
Leuk Res. 2012 May;36(5):581-7
pubmed: 22386729
J Immunol. 2003 Nov 15;171(10):5264-71
pubmed: 14607927
Front Immunol. 2014 Feb 26;5:72
pubmed: 24616720
Nat Immunol. 2016 Sep;17(9):1067-74
pubmed: 27455421
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10160-5
pubmed: 20439706
Pan Afr Med J. 2019 Oct 29;34:119
pubmed: 31934260
Leukemia. 2007 May;21(5):1060-9
pubmed: 17361229
Br J Haematol. 2020 Feb;188(4):522-527
pubmed: 31608437
Gulf J Oncolog. 2018 Jan;1(26):72-74
pubmed: 29607828
Blood Cancer J. 2020 Apr 22;10(4):42
pubmed: 32321919
Trends Genet. 2013 Oct;29(10):593-9
pubmed: 23972387
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500
Leukemia. 2019 Jun;33(6):1451-1462
pubmed: 30546078
Blood. 1997 Sep 1;90(5):1977-81
pubmed: 9292532
Blood. 2003 Sep 1;102(5):1797-805
pubmed: 12750175

Auteurs

Edoardo Giussani (E)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Andrea Binatti (A)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Giulia Calabretto (G)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Vanessa Rebecca Gasparini (VR)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Antonella Teramo (A)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Cristina Vicenzetto (C)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Gregorio Barilà (G)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Monica Facco (M)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Alessandro Coppe (A)

Department of Maternal and Child Health, University of Padova, Padova, Italy.
Department of Biology, University of Padova, Padova, Italy.

Gianpietro Semenzato (G)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Stefania Bortoluzzi (S)

Department of Molecular Medicine, University of Padova, Padova, Italy.
CRIBI Biotechnology Centre, University of Padova, Padova, Italy.

Renato Zambello (R)

Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Classifications MeSH